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A N S W E R S A N D D I S C U S S I O N
1. Splenectomy was performed on the 58th day
of pyrexia, as the patient was clinically unre-
sponsive to amphotericin B and the bulk of
the remaining lesions were in the spleen (Figure
1). An immediate febrile response was obtained
24 h following splenectomy. Liposomal ampho-
tericin was replaced with maintenance ther-
apy of 6 mg/kg per day oral fluconazole post-
splenectomy. Pathologic examination of the
spleen revealed extensive candida abscesses
(Figure 2). However, splenic tissue cultures
remained negative, most probably due to the
prolonged antifungal therapy. Liver transami-
nase levels gradually returned to normal, and
abdominal CT following 2 months of flucona-
zole treatment revealed no further lesions and
marked regression of the few remaining liver
and kidney abscesses. Fluconazole treatment
was continued for a total of 6 months. A CT scan
at the end of this period showed complete reso-
lution of the lesions. Following his distressing
ordeal, the patient refused further consolidation
chemotherapy, but he remains in complete
remission in terms of both AML and CDC
12 months following the reinduction che-
motherapy. Predominant involvement of the
spleen with little or no involvement of the liver
by candida abscesses has been previously
described as a less typical presentation of
CDC in patients with hematologic malignancies
[1,2], and splenectomy had a beneficial effect in
conjunction with antifungal therapy in some of
these patients [1–3]. This case illustrates that
splenectomy may have a role in a minority of
patients who are unresponsive to antifungal
treatment and have the bulk of their lesions in
the spleen.
2. The most appropriate therapeutic regimens and
endpoints of treatment for CDC are not yet
adequately defined, as CDC is a relatively
uncommon disease, and controlled trials are
difficult to conduct. Historically, the usual ther-
apy for CDC has been amphotericin B deoxy-
cholate. There is general agreement on the
treatment dose of 0.7 mg/kg per day for
amphotericin B deoxycholate, and some inves-
tigators would use higher doses, up to 1.5 mg/
kg per day, for unstable patients [4]. Previous
studies reported total amphotericin B deoxycho-
late doses ranging from 1.6 to 4 g prior to deter-
mination of non-response and change of
therapy [5–7]. However, in almost 50% of the
cases, administration for periods of up to
6 months and up to a total dose of 6 g was still
not adequate to stop the infection from progres-
sing [6,7]. The clinical progress of the patient is
important in the timing of change of therapy.
The frequent failure of this therapy may be
related to the pharmacokinetics of amphotericin
B deoxycholate, as candida infection can persist
in the liver despite adequate concentrations of
the drug [8]. In addition, prolonged amphoter-
icin B deoxycholate therapy can lead to consid-
erable toxicity, especially renal [6,7]. The patient
in this presentation had severe uncontrolled
hypokalemia with amphotericin B deoxycho-
late, which was replaced with liposomal
amphotericin B. Lipid formulations of ampho-
tericin B are approved for second-line therapy of
patients who are intolerant of, or refractory to,
therapy with conventional amphotericin B.
Walsh et al. suggested that this could be due
to the failure of 500 mg amphotericin B, initial
renal insufficiency (creatinine 2.5 mg/dL or
creatinine clearance <25 mL/min), a significant
rise in creatinine (to 2.5 mg/dL in adults or
1.5 mg/dL in children), or severe acute admin-
istration-related toxicity [9]. Lipid formulations
of amphotericin B permit administration of the
drug at much higher doses, and they are also
targeted naturally to the liver and spleen, which
promotes their selective interactions with the
Candida membrane [10]. Both in vivo and clinical
studies indicate that these compounds are less
toxic than, but as effective as, amphotericin B
[11,12]. Nevertheless, their high cost and the
lack of randomized trials in proven invasive
candidiasis limit their front-line use [13]. The
optimal dose of these compounds for serious
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candida infections is unclear, but 3–5 mg/kg
appears to be suitable for most candidal infec-
tions [13].
3. Fluconazole, which is readily absorbed from the
gastrointestinal tract and distributed widely in
body tissues, including the liver, spleen and
kidneys, has a response rate of about 80%,
and is effective even among patients who failed
to respond to previous amphotericin B treat-
ment [6,14]. It is believed that fluconazole
should be the drug of choice for CDC, because
it is at least as effective as amphotericin B, is less
toxic, can be given orally, and is less expensive
than the lipid formulations of amphotericin B
[4,15]. C. albicans is the causative agent in the
majority of cases, but C. krusei, C. tropicalis, C.
glabrata and other Candida species are increas-
ingly responsible for invasive candidiasis [16].
C. albicans is commonly sensitive to fluconazole,
but non-albicans Candida spp. may be resistant
and require treatment with amphotericin B (par-
ticularly C. krusei and C. glabrata). Susceptibility
of Candida to the available antifungal agents can
be predicted if the species of the infecting isolate
is known [16–18], but data correlating the clin-
ical outcome of therapy with in vitro suscept-
ibility are not precise [13]. Therapy in this case
was initiated with fluconazole, but it was chan-
ged to amphotericin B deoxycholate following
the isolation of non-albicans Candida species;
esophageal cultures yielded C. krusei, known
to be intrinsically resistant to fluconazole [19].
Fluconazole was recommenced post-splenect-
omy, as splenic tissue was assumed to be
infected by the blood culture isolate C. kefyr,
which is known to be sensitive to fluconazole
as well as amphotericin B [20,21]. An oral dose of
6 mg/kg per day was chosen. Although dose-
ranging studies for fluconazole have not been
performed in patients with candidemia or deep
candidal infections, most experts would initiate
therapy at 6 mg/kg per day in stable patients
who have not recently received azole therapy
[13]. Duration of therapy should be highly indi-
vidualized, and typically should be about
6 months [22].
In conclusion, Fluconazole is the treatment of
choice for C. albicans, but treatment response is
unknown for non-albicans Candida spp., which
may require treatment with amphotericin B deox-
ycholate or a lipid formulation of amphotericin
Figure 1 Abdominal CT scans showing numerous hypo-
dense lesions within the spleen, and few lesions in the liver
and kidney, consistent with abscesses.
Figure 2 Postsurgical dissection of the spleen demonstrat-
ing multiple candida abscesses.
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B. Splenectomy has a role in a minority of pati-
ents who are unresponsive to antifungal treat-
ment and have the bulk of their lesions in the
spleen.
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